Table 1B.
Demographics | mRNA cohort | Protein cohort | ||||||
---|---|---|---|---|---|---|---|---|
Control (28) | SCZ low inflammatory (15) | SCZ high inflammatory (13) | Statistics | Control (26) | SCZ low inflammatory (13) | SCZ high inflammatory (12) | Statistics | |
Age (years) | 50.54 | 48.27 | 54.92 | χ2(2) = 2.81, p = 0.25 | 51.19 | 49.31 | 56.17 | χ2(2) = 2.89, p = 0.24 |
(22–67) | (30–64) | (26–67) | (22–67) | (30–64) | (26–67) | |||
Gender (M, F) | (20,8) | (11,4) | (8,5) | – | (19,7) | (9,4) | (7,5) | – |
pH | 6.66 ± 0.26 | 6.52 ± 0.20 | 6.49 ± 0.20 | χ2(2) = 8.51, p = 0.014* | 6.69 ± 0.22 | 6.54 ± 0.20 | 6.52 ± 0.18 | F(2, 48) = 4.02, p = 0.024* |
PMI (hours) | 31.68 ± 10.21 | 33.43 ± 14.66 | 38.23 ± 21.01 | F(2, 53) = 0.91, p = 0.41 | 33.42 ± 10.21 | 35.19 ± 14.93 | 39.62 ± 21.30 | F(2, 48) = 1.00, p = 0.38 |
(range) | (15–50) | (18–64) | (5–72) | (15–50) | (18–64) | (5–72) | ||
RIN | 5.56 ± 1.15 | 5.53 ± 1.28 | 5.70 ± 1.39 | F(2, 53) = 0.079, p = 0.92 | – | – | – | – |
Duration of illness | – | 26.43 ± 11.65 | 31.62 ± 13.926 | t(26) = −1.073, p = 0.29 | – | 25.92 ± 11.30 | 32.33 ± 14.29 | t(22) = −1.220, p = 0.24 |
Daily CPZ (mg) | – | 483.54 ± 177.63 | 1039.93 ± 637.06 | t(10.169) = 2.68, p = 0.023* | – | 422.30 ± 116.23 | 1043.11 ± 675.69 | U = 81.0, p = 0.002*** |
Last recorded CPZ (mg) | – | 361.53 ± 316.56 | 869.85 ± 538.82 | U = 156.5, p = 0.005** | – | 391.00 ± 331.35 | 860.17 ± 561.60 | U = 210.5, p = 0.019* |
Lifetime CPZ (g) | – | 4204.952 ± 2170.41 | 13063.22 ± 11129.88 | U = 100.0, p = 0.007** | – | 3799.83 ± 1800.43 | 13570.25 ± 11681.88 | U = 77.0, p = 0.008** |
F, female; M, male; PMI, postmortem interval; RIN, RNA integrity; SCZ, schizophrenia, Data are mean ± s.d. Age and PMI ranges are in brackets. Bold values indicate significant changes. ∧Control group sizes are different in the cohorts as there is no inflammatory biotype for 2 cases that were included in the protein cohort but excluded from the mRNA cohort due to poor qPCR data.
p < 0.05,
p < 0.01,
p < 0.001.